Indications › Substance use › semaglutide
semaglutide in substance use
semaglutide is not approved in the US for substance use, and has 11 trials on file here in this condition. 1 of them is phase 3 or later. The next scheduled result is 2027-01. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.
11 registered trials study semaglutide (Rybelsus, Wegovy, Ozempic) in substance use, 9 of them still active and 1 in phase 3. The next is due to report 2027-04-30.
- Trials on file
- 11
- Active
- 9
- Active phase 3
- 1
- Participants in active trials
- 826
- Sponsors
- 11
- Scheduled readouts
- 2
Scheduled to report
Dates are filed by the sponsor and move often. Each links to its own record and change history.
| Est. completion | Trial | Phase | Participants |
|---|---|---|---|
| 2027-04-30 | GLP-1R Agonist Treatment for Opioid Use Disorder NCT06548490 · Milton S. Hershey Medical Center | P2 | 200 |
| 2028-04-30 | Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder NCT07523633 · Anders Fink-Jensen, MD, DMSci | P2 | 100 |
All trials on file
Every registered trial of semaglutide grouped under substance use, largest first. Grouping follows the registry’s own condition wording.
See the full record for semaglutide, or every molecule being studied in substance use. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.